A combination treatment of gefitinib and the HER2-HER3 dimerization inhibitor pertuzumab showed more effective growth inhibition than gefitinib alone on gefitinib-resistant HNSCC cell lines [107]. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.